Pediatric Dermatology Part II, An Issue of Dermatologic Clinics , E-Book : Pediatric Dermatology Part II, An Issue of Dermatologic Clinics , E-Book

著者名：Cordoro MD, Kelly M. (EDT)

Elsevier（2022/04/08発売）

• 言語：ENG
• ISBN：9780323897624
• eISBN：9780323897631

Description

In this issue of Dermatologic Clinics, guest editor Dr. Kelly M. Cordoro brings her considerable expertise to the topic of Pediatric Dermatology. Top experts in the field cover key topics such as neutrophilic dermatoses in children; laser surgery for dermatologic conditions in pediatric patients; managing children/families with delusions of infestation/parasitosis; counterfeit medications; and more.- Contains 11 relevant, practice-oriented topics including clinical relevance of the cutaneous microbiome in pediatric skin disease; systemic therapy for vascular malformations and the status of genotype-guided management; systemic therapy for pediatric atopic dermatitis; update on biologic therapy for pediatric psoriasis; hormonal treatment of acne in adolescent patients; and more. - Provides in-depth clinical reviews on pediatric dermatology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. 

Table of Contents

Clinical Relevance of the Microbiome in Pediatric Skin Disease: A ReviewSystemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided ManagementEvolving Landscape of Systemic Therapy for Pediatric Atopic DermatitisClinical Decisions in Pediatric Psoriasis: A Practical Approach to Systemic TherapyHormonal Treatment of Acne and Hidradenitis Suppurativa in Adolescent PatientsSweet Syndrome in the Pediatric PopulationMorbilliform Eruptions in the Hospitalized ChildSupportive Oncodermatology in Pediatric PatientsLaser Surgery for Dermatologic Conditions in Pediatric PatientsDermatologic Consequences of Substandard, Spurious, Falsely Labeled, Falsified, and Counterfeit Medications